Chronic Myelomonocytic Leukaemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Chronic Myelomonocytic Leukaemia Pipeline Insight 2024" report provides comprehensive insights about 22+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Myelomonocytic Leukaemia Research. Learn more about our innovative pipeline today! @ Chronic Myelomonocytic Leukaemia Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report

* June 2024:- Douglas Tremblay- This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received less than or equal to 1 cycle.
* June 2024:- Novartis Pharmaceuticals - An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
* June 2024:- M.D. Anderson Cancer Center- This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received prior treatment (treatment-naive). Chemotherapy drugs, such as venetoclax, cedazuridine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
* June 2024:- Otsuka Australia Pharmaceutical Pty Ltd- A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.
* June 2024:- Astex Pharmaceuticals, Inc.: - Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B) of ASTX030. Phase 2 is a randomized open-label crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the final oral ASTX030 dose to SC azacitidine. The duration of the study is expected to be approximately 48 months.
* June 2024:- Cogent Biosciences, Inc.- A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis. This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
* DelveInsight's Chronic Myelomonocytic Leukaemia pipeline report depicts a robust space with 22+ active players working to develop 25+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.
* The leading Chronic Myelomonocytic Leukaemia Companies such as Novartis, Humanigen, Incyte Corporation, Genetech, Celgene, AbbVie, Amgen, Nerviano Medical Sciences, Guangzhou Lupeng Pharmaceutical , and others.
* Promising Chronic Myelomonocytic Leukaemia Therapies such as Bezuclastinib, CPX-351, Cyclophosphamide, Cyclosporine, Azacitidine, Enasidenib, APG 2575 ramp up arm , and others.

Stay informed about the cutting-edge advancements in Chronic Myelomonocytic Leukaemia Treatments. Download for updates and be a part of the revolution in cancer care @ Chronic Myelomonocytic Leukaemia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Myelomonocytic Leukaemia Emerging Drugs Profile

* Sabatolimab: Novartis

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. Currently, the drug is in Phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

* Ruxolitinib: Incyte Corporation

Ruxolitinib (Jakafi) is a first-in-class inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in proinflammatory cytokines and chemokines. In the clinical study, Ruxoltinib demonstrated meaningful clinical activity in CMML patients with splenomegaly and/or high disease symptom burden. The drug is already approved by the US Food and Drug Administration for the treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Jakafi is also indicated for the treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The drug is currently in Phase II stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

* NMS-03592088: Nerviano Medical Sciences

NMS-03592088 (NMS-088) is a potent inhibitor of FLT3, KIT, and CSF1R kinases. NMS-088 is the most active compound among the FLT3 comparators, a finding especially evident in the presence of the FLT3 "gatekeeper mutation," which is associated with clinical resistance to treatment with other FLT3 inhibitors. There is a rationale for the use of the molecule in Chronic Myelomonocytic Leukemia (CMML) on the basis of the demonstrated inhibition of CSF1R, a highly expressed and activated target in this tumor type. The drug is currently in the Phase I/II stage of development for the treatment of CMML.

* LP-108: Guangzhou Lupeng Pharmaceutical

LP-108 is a proto-oncogene protein (c-bcl-2) inhibitor. The drug is currently in Phase I stage of development for the treatment of CMML.

Learn more about Chronic Myelomonocytic Leukaemia Drug opportunities in our groundbreaking Chronic Myelomonocytic Leukaemia Research and development projects @ Chronic Myelomonocytic Leukaemia Unmet Needs [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Myelomonocytic Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Chronic Myelomonocytic Leukaemia Treatment by visiting our website. Stay informed about how we're transforming the future @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Myelomonocytic Leukaemia Companies and Therapies

* Cogent Bioscience Inc.:- Bezuclastinib
* Ascentage Pharma Group Inc.:- APG 2575 ramp up arm
* BioLite Inc.:- BLEX 404 Oral Liquid
* Astex Pharmaceuticals Inc.:- Azacitidine

Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report

* Coverage- Global
* Chronic Myelomonocytic Leukaemia Companies- Novartis, Humanigen, Incyte Corporation, Genetech, Celgene, AbbVie, Amgen, Nerviano Medical Sciences, Guangzhou Lupeng Pharmaceutical, and others.
* Chronic Myelomonocytic Leukaemia Therapies- Bezuclastinib, CPX-351, Cyclophosphamide, Cyclosporine, Azacitidine, Enasidenib, APG 2575 ramp up arm, and others.
* Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Myelomonocytic Leukaemia Pipeline on our website @ Chronic Myelomonocytic Leukaemia Drugs and Companies [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Chronic Myelomonocytic Leukaemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Myelomonocytic Leukaemia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sabatolimab : Novartis
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ruxolitinib: Incyte Corporation
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* NMS-03592088: Nerviano Medical Sciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Chronic Myelomonocytic Leukaemia Key Companies
* Chronic Myelomonocytic Leukaemia Key Products
* Chronic Myelomonocytic Leukaemia- Unmet Needs
* Chronic Myelomonocytic Leukaemia- Market Drivers and Barriers
* Chronic Myelomonocytic Leukaemia- Future Perspectives and Conclusion
* Chronic Myelomonocytic Leukaemia Analyst Views
* Chronic Myelomonocytic Leukaemia Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-myelomonocytic-leukaemia-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.